- SynonymFc gamma RIIIB,CD16b (NA2),FCGR3B,CD16B,FCG3B,FCGR3,FCG3,IGFR3
- SourceHuman CD16b (NA2), His Tag (SPR & BLI verified) (CDB-H5222) is expressed from human 293 cells (HEK293). It contains AA Gly 17 - Ser 200 (Accession # O75015-1).The NA1 form of the CD16b differ with the NA2 form of CD16b in AA36, 65, 82, and 106. The NA1 form carries R36, N65, D82, and V106, while the NA2 form carries S36, S65, N82, and I106.Predicted N-terminus: Gly 17Request for sequence
- Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.7 kDa. The protein migrates as 38-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human CD16b (NA2), His Tag (SPR & BLI verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human CD16b (NA2), His Tag (SPR & BLI verified) (Cat. No. CDB-H5222) on CM5 Chip via anti-His antibody, can bind Rituximab with an affinity constant of 2.88 μM as determined in a SPR assay (Biacore T200) (QC tested).
Loaded Human CD16b (NA2), His Tag (SPR & BLI verified) (Cat. No. CDB-H5222) on HIS1K Biosensor, can bind Rituximab with an affinity constant of 7.1 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
- Citations
Control of therapeutic IgG antibodies galactosylation during cultivation process and its impact on IgG1/FcγR interaction and ADCC activity
Authors: Simonov V, et al
Journal: Biologicals 43480
Application: SPR
Request for Full-text
- BackgroundCD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.CD16B is also kown as FCGR3B and FCG3B, is expressed specifically by polymorphonuclear leukocytes (neutrophils) and stimulated eosinophils. CD16B is the low affinity receptor for the Fc region of immunoglobulins gamma. FCGR3B binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, FCG3B is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. CD16B may serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
